Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

The DAPA HF trial evaluated the efficacy and safety of dapagliflozin, an SGLT2 inhibitor, in patients with heart failure and reduced ejection fraction (≤40%), with or without type 2 diabetes. The study involved 4744 patients followed for a median of 18.2 months. Results showed that dapagliflozin significantly reduced the primary composite outcome of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death (16.3% vs. 21.2%; hazard ratio, 0.74; 95% CI, 0.65–0.85; P<0.001). The benefits were consistent across subgroups, including patients without diabetes. Dapagliflozin also improved heart failure symptoms and reduced the risk of cardiovascular death and all cause mortality. Safety profiles were similar between groups, with no significant differences in volume depletion, renal adverse events, or hypoglycemia. These findings suggest dapagliflozin as a beneficial treatment for heart failure, independent of diabetes status.

The DAPA HF trial evaluated the efficacy and safety of dapagliflozin, an SGLT2 inhibitor, in patients with heart failure and reduced ejection fraction (≤40%), with or without type 2 diabetes. The study involved 4744 patients followed for a median of 18.2 months. Results showed that dapagliflozin significantly reduced the primary composite outcome of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death (16.3% vs. 21.2%; hazard ratio, 0.74; 95% CI, 0.65–0.85; P<0.001). The benefits were consistent across subgroups, including patients without diabetes. Dapagliflozin also improved heart failure symptoms and reduced the risk of cardiovascular death and all cause mortality. Safety profiles were similar between groups, with no significant differences in volume depletion, renal adverse events, or hypoglycemia. These findings suggest dapagliflozin as a beneficial treatment for heart failure, independent of diabetes status.